The Latest Breaking News from GSK

The medical industry is set for significant growth due to technological advances, increased demand for medicines due to an aging population, escalating healthcare costs, and the rising need for quality healthcare. Therefore, it could be wise to buy fundamentally strong medical stocks GSK (GSK), National HealthCare (NHC), and MiMedx Group…

GSK breathes new life into respiratory portfolio with the acquisition of Aiolos Bio in an impressive GSK Supercharges Respiratory Line with Top News.4B Aiolos Bio Acquisition.4 billion deal. Innovation keeps us breathing easy!

Flovent — a common asthma inhaler — will be discontinued in 2024. There will be a generic version available, but the change could make it hard for some patients to get their medication.

GSK, the pharmaceutical giant, is taking a bold step by announcing price reductions for popular drugs Advair, Valtrex, and Lamictal in the US. A refreshing...

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach for its vaccines.

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

Amid the burgeoning technological innovation and its seamless integration, investors' interest seems to gravitate toward the pharmaceutical industry. Keeping this in mind, which of the stocks, SNDL Inc. (SNDL) and GSK plc (GSK), could be a better long-term investment? Let's find out.

People should not die because of their income or where they were born. We must have the courage to stand up to the pharmaceutical industry

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….